SCHEMBL4393067

SCHEMBL4393067

CN(c1ccc(S(=O)(=O)N2CCC(=NOCc3ccc(NCC4CC4)c(C#N)c3)CC2)cc1)C1CC1

nearest known ligand 0.32

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SCN5A Q14524 1/20 0.32
MEN1 O00255 1/20 0.31
KMT2A Q03164 1/20 0.31
MAPT P10636 1/20 0.31
BRD4 O60885 1/20 0.31
ALDH1A1 P00352 3/20 0.31
KDM4E B2RXH2 1/20 0.31
HPGD P15428 1/20 0.31
MAPK1 P28482 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
TDP1 Q9NUW8 1/20 0.31
L3MBTL1 Q9Y468 1/20 0.31
CCNA2 P20248 1/20 0.30
CDK2 P24941 1/20 0.30
HSD11B1 P28845 1/20 0.30
RORC P51449 1/20 0.30
CFTR P13569 1/20 0.30
GAA P10253 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4393069 0.88 ALDH1A1 (0.35) SCN5AMEN1KMT2AMAPTALDH1A1
SCHEMBL4392962 0.81 ADAM17 (0.40) MEN1KMT2AMAPTALDH1A1SMN1; SMN2
SCHEMBL4384886 0.76 PKM (0.38) MEN1KMT2AMAPTALDH1A1KDM4E
SCHEMBL4392967 0.74 ADAM17 (0.41) MEN1KMT2AMAPTALDH1A1SMN1; SMN2
SCHEMBL4381060 0.74 TP53 (0.37) MEN1KMT2AMAPTALDH1A1KDM4E
SCHEMBL4383813 0.73 RORC (0.43) MEN1KMT2AMAPTALDH1A1KDM4E
SCHEMBL4385274 0.72 PKM (0.41) MEN1KMT2AMAPTALDH1A1SMN1; SMN2
SCHEMBL4382701 0.70 PKM (0.47) MEN1KMT2AALDH1A1KDM4ESMN1; SMN2
SCHEMBL4385346 0.69 MEN1 (0.43) MEN1KMT2ASMN1; SMN2RORCGAA
SCHEMBL4380375 0.68 CCR6 (0.45) ALDH1A1KDM4ESMN1; SMN2CCNA2CDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090298878-A1 OXIME COMPOUNDS AND THE USE THEREOF PURDUE PHARMA L.P. 2009-12-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090298878-A1 OXIME COMPOUNDS AND THE USE THEREOF KCNN4, CACNA1A, KCNN3 SCN5A 208/4885MEN1 3694/4885KMT2A 2079/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.